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Abstract
The imprinted gene PLAGL1 is an important regulator of apoptosis and cell cycle arrest.
Loss of its expression has been implicated in tumorigenesis in a range of different cancers,
and overexpression during fetal development causes transient neonatal diabetes mellitus
(TNDM). PLAGL1 lies within an imprinted region of chromosome 6q24, and monoallelic
expression from the major, differentially methylated promoter (P1) occurs in most human tis-
sues. However, in peripheral blood leukocytes, the active promoter (P2) is non-imprinted
and drives biallelic transcription. We report here a novel PLAGL1 promoter (P5) derived
from the insertion of a primate-specific, MIR3 SINE retrotransposon. P5 is highly utilized in
lymphocytes, particularly in T cells, and like P2, directs biallelic transcription. Our results
show that it is important to consider P5 in relation to PLAGL1 function in T cells when investi-
gating the dysregulation of this gene.
Introduction
Genomic imprinting is an epigenetic process by which specific genes are expressed preferen-
tially according to their parent of origin. PLAGL1 (also known as ZAC, LOT1 and Zac1 in
mouse) is an imprinted gene that is a key regulator of a network of other imprinted genes,
involved in embryonic growth and development [1]. At a biochemical and cellular level,
PLAGL1 protein both acts as a transcriptional co-activator for p53 and regulates cell cycle and
apoptosis concomitantly [2,3]. Dysregulation of this gene plays a pathogenic role in the tumor-
igenesis of several types of cancer and in a rare form of childhood diabetes, transient neonatal
diabetes mellitus (TNDM1; OMIM #601410) [4]. There is evidence that PLAGL1 acts as a
tumour suppressor in many tissues, as down-regulation has been observed in a range of differ-
ent tumours, through hypermethylation of the imprinted promoter, chromosomal deletion or
loss of heterozygosity [2,3]. Conversely, PLAGL1 can also act as an oncogene in glioblastoma
[5].
Most imprinted genes are located in clusters, across which there are some degrees of co-
ordinate gene regulation; however, the PLAGL1 locus on chromosome 6q24 has been shown
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to be a “micro-imprinted” domain [6]. It contains a differentially methylated region (DMR)
that acts as a promoter (P1) directing transcription from the unmethylated, paternal allele in
most human and mouse tissues [2]. Monoallelic expression occurs in most human fetal and
adult tissues, with biallelic expression in peripheral blood leukocytes [4,7,8]. Over-expression
of PLAGL1 during fetal development, either secondary to paternal uniparental disomy of 6q24
or due to epigenetic alterations at the PLAGL1 DMR, causes TNDM [2,4].
Previously, we defined and characterised a second promoter (P2) located within an
unmethylated CpG island of human PLAGL1. Unlike P1, P2 drives biallelic transcription and
is utilized predominantly in peripheral blood leukocytes [7]. Where detectable, P2 transcrip-
tion is similarly biallelic in other human tissues [7]. We found that P2-derived PLAGL1 expres-
sion is down-regulated in some cases of diffuse large B-cell lymphoma and the mechanism of
the down-regulation did not involve hypermethylation of the P2 CpG island [9]. In addition,
two minor, intragenic promoters have also been identified (P3 and P4), that like P1, produce
paternally-expressed transcripts [6]. Although the biological drivers for the existence of multi-
ple PLAGL1 promoters are unclear, it appears that they may control tissue-specific expression
or act as a protective mechanism to prevent loss of PLAGL1 expression in some tissues. In this
study, we have identified a fifth promoter region (P5), from which transcripts are highly
expressed in lymphocytes, particularly T cells.
Results and discussion
PLAGL1 transcripts are generated from a novel, fifth promoter
The present work was prompted by the existence of three novel spliced PLAGL1 ESTs that
appear to initiate at a novel genomic location lying between the differentially methylated (P1)
promoter and the upstream, unmethylated promoter (P2). These ESTs range in length from
519-560-bp and were derived from peripheral blood mononuclear cells (accession number
DA814732), thymus (DB104173) and kidney tumour tissue (DB177852) [10]. Sequence align-
ment indicated that they share a novel 50 exon (>45-bp in size), that was neither annotated as
part of a PLAGL1 50-UTR in the UCSC genome browser, nor had been previously observed by
us in transcripts isolated from several human tissues [7]. The DB177852 EST also contains a
unique second exon, not observed in PLAGL1 transcripts originating from P2. The remaining
sequence in the EST transcripts aligned with known exons that constitute the 50-UTR of
PLAGL1; none of these ESTs extend as far as the PLAGL1 coding region at their 3’ ends. More
recently, the sequence data from these ESTs have been combined in the UCSC genome
browser as a curated transcript attributed to PLAGL1: NM_001317159.
PLAGL1 expression from the P5 promoter is highly expressed in T cells
We designate the putative new PLAGL1 promoter from which these three ESTs derive as P5.
We assessed its utilization by semi-quantitative RT-PCR, and compared it to P1 and P2 pro-
moter activity in a panel of RNAs from a range of human tissues (Fig 1A). PLAGL1 transcripts
were amplified from each promoter separately, using a forward primer specific for either the
P1, P2 or P5 50-UTR exon, combined with a common reverse primer located in the coding
region within the last exon. For each tissue, the PCR reactions were run in adjacent lanes on
agarose gels for comparison with each other (Fig 1A). Specificity of transcripts derived from
each promoter was confirmed by cloning and sequencing a sample of PCR products (data not
shown).
Consistent with our previous study [7], we found that PLAGL1 was expressed predomi-
nantly from the P1 promoter in most tissues, with a low level of P2 transcripts in some, such as
spleen and lung (Fig 1A). The transcripts captured by the RT-PCR reaction vary in size due to
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Fig 1. Fig 1A: Comparison of PLAGL1 transcription derived from three alternative promoters (P1; P2;
P5) in a panel of human tissues. For each tissue, three individual RT-PCR reactions were performed, using
primers that specifically amplify transcripts from P1 (lane ‘1’), P2 (lane ‘2’) or P5 (lane ‘5’) (See Materials and
methods). The top two panels show PLAGL1 in cDNA samples: Ov, ovary; Ki, kidney; Th, thymus; Co, colon;
He, heart; Li, liver; Br, brain; Pr, prostate; Sp, spleen; Pl, placenta; Ad, adipose tissue; Bl, bladder; Ce, cervix;
Oe, oesophagus; Lu, lung; Sk, skeletal muscle; Sm, small intestine; Te, testes; Th, thyroid; Tr, trachea; Pa,
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complex alternative splicing of the 5’-UTR, and two main species are represented, that differ
by ~475-bp due to inclusion or exclusion of the penultimate coding exon. These two mRNA
classes encode the long and short PLAGL1 isoforms, with five zinc fingers present in the short
isoform of the protein compared to seven zinc fingers in the long isoform [11]. P5 transcripts
appeared to be rare compared to P1 or P2 transcripts, and were absent or barely detectable in
all tissues, with only primer-dimer bands evident in the P5 lanes (Fig 1A). For P1 and P2
expression, the results are in general agreement with our previous observations in these tissues,
as determined by qPCR [7].
As two of the deposited ESTs had been derived from cells of haemopoietic origin, we per-
formed a similar analysis using an RNA panel from a range of blood cell types: peripheral
blood leukocytes, CD14+, activated CD4+ and activated/non-activated samples of CD8+ and
CD19+ cells (Fig 1B). RNA from non-activated CD4+ cells was not tested. In all samples tested
(except CD8+ cells), PLAGL1 was expressed more highly from the P2 promoter than P1, in
agreement with our previous observations [7,9]. PLAGL1 expression was only just detectable
in NK cells. P2 promoter activity was predominant in peripheral blood leukocytes, CD14+
monocytes, and activated/non-activated CD19+ B cells. Expression from P5 was detectable in
these cell types at a low level (Fig 1B) and primer-dimer bands were present, as in Fig 1A.
However, in T cells (CD4+ and CD8+ samples) we observed particularly high expression from
the P5 promoter. In all three samples (activated CD4+ cells; activated and non-activated CD8+
cells), this promoter was utilized at a higher or equivalent level to the blood cell-specific P2
promoter (Fig 1B).
To confirm the utilization of the P5 promoter in lymphocytes, we undertook qPCR using
blood cell RNA samples and compared them with two other human tissues, pancreas and pla-
centa, that express PLAGL1 [7]. A custom-made Taqman assay was designed specifically to
amplify P5 transcripts, and activated CD4+ cDNA was used to generate standard curves (due
to its high expression level of P5) for the absolute quantification method. Expression of P5 was
normalised to expression of the endogenous control gene, RPLP0. NK cells were not tested.
QPCR results showed highest expression of P5 transcripts in activated CD4+ cells and non-
activated CD8+ cells, with lower levels in leukocytes and activated CD8+ cells (Fig 1C). P5
expression was observed in all blood cell types tested. P5 transcripts were not expressed in pan-
creas or placenta although high expression levels of RPLP0 were observed, acting as a positive
control. These qPCR data broadly agreed with our RT-PCR results, indicating that P5 tran-
scripts are expressed predominantly in blood cells, particularly T cells. Some variability in
expression levels between Fig 1B and 1C was observed: for example, P5 expression in activated
CD8+ cells appeared lower by qPCR (Fig 1C) compared to RT-PCR (Fig 1B). This may be due
to minor variation between RNA samples, as a second set of RNAs were used for qPCR
pancreas. The molecular weight marker is GeneRuler 100bp+ ladder (Invitrogen). PLAGL1 transcripts are
subject to complex alternative splicing of the 50-UTR, and the two major bands (arrowed) result from alternative
splicing of the coding exons. The third panel down shows RT-PCR of the housekeeping gene RPLP0 as a
loading control for each reaction. All non-template (water) controls were negative. Fig 1B: Comparison of
PLAGL1 transcription from the three alternative promoters in primary blood cells. cDNA samples:
leukocytes (peripheral blood leukocytes); CD14+ cells (monocytes); activated CD4+ cells (T helper/inducer
cells); CD8+ cells (T suppressor/cytotoxic cells); activated CD8+ cells; CD19+ cells (B-lymphocytes); activated
CD19+; NK cells (see Materials and methods). The panel below shows RPLP0 as loading controls for each
reaction. All non-template controls were negative. Fig 1C: qPCR analysis of promoter P5 transcription in a
range of blood cell RNAs, compared with pancreas and placenta tissue. The expression levels of P5
transcripts were normalised to that of the endogenous control gene RPLP0 in each sample, and are expressed
in arbitrary units. Fig 1D: qPCR analysis of promoter P2 transcription using the same cDNA samples as
in Fig. 1C, for comparison. Similar to the P5 qPCR, expression levels were normalised to RPLP0 expression,
and are in arbitrary units.
https://doi.org/10.1371/journal.pone.0185678.g001
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compared to those previously used for RT-PCR, although samples were obtained from the
same commercial source. Alternatively, there may be small differences in detection of alterna-
tively-spliced P5 transcripts using the two techniques.
For comparison with Fig 1C, we used the same cDNAs to detect P2 transcripts, using a Taq-
man assay specific to P2 transcripts, as described previously [7] (Fig 1D). Lower levels of P2
expression in CD4+ activated cells necessitated using leukocyte cDNA for standard curves,
therefore these data are presented on separate graphs. The highest levels of P2 transcripts were
detected in leukocytes and CD14+ cells, with low levels in all of the blood cell samples tested.
P2 expression was detected in all blood cell types tested but not in pancreas or placenta, con-
firming our previous observations [7]. P1 expression was not tested due to limited availability
of RNA, although we would predict little or no P1 expression in blood cells and high levels in
pancreas and placenta, based on our RT-PCR results (Fig 1A and 1B).
Overall, PLAGL1 transcripts derived from the P5 promoter were found to be highly
expressed in T cells, and in B cells to a lesser extent, compared to other blood cells or tissues.
We also observed that transcripts encoding the long protein isoform were expressed predomi-
nantly in CD8+ cells (Fig 1B). This isoform, with seven zinc fingers, possesses a greater ability
than the short form (referred to as PLAGL1Δ2) to induce apoptosis, suggesting that this may
be a particular function of the protein in this cell type [11].
P5-derived RT-PCR products from activated CD4+ and activated CD19+ cell RNA were
purified, cloned and sequenced to confirm that they were genuine PLAGL1 transcripts. As for
Fig 1B, transcripts were amplified using a forward primer in the P5 exon in combination with
a reverse primer in the final coding exon. Sequencing confirmed that P5 transcripts extend to
the PLAGL1 coding region (Fig 2). Complex alternative splicing of the 50-UTR was observed,
and both the long (PLAGL1) and short (PLAGL1Δ2) protein isoforms were represented. Short
protein isoforms predominated, which may be due to cloning bias of smaller transcripts. Our
cloning strategy was not exhaustive and these transcripts may represent only a proportion of
the alternatively spliced variants produced in these cell types.
Confirmation of P5 transcriptional start sites (TSS) in B and T
lymphocytes
To confirm that P5 represents a novel promoter region and does not splice to exons farther
upstream within the PLAGL1 50-UTR, we carried out 50-RLM-RACE to determine the TSS for
P5. As P5 expression is most abundant in lymphocytes, we used RNA derived from activated
CD4+ cells (T lymphocytes) and activated CD19+ cells (B lymphocytes). The 50-UTR of
PLAGL1 is subject to complex alternative splicing, but we have previously noted a ubiquitous
72-bp exon that appears to be obligatory (previously designated ‘exon 3a’) [7]. Therefore,
RLM-RACE was carried out using nested reverse primers designed to this exon, combined
with nested forward primers to the adaptor sequence (see Materials and methods).
Sequencing of the resulting PCR products showed the transcripts to be derived from the P2
or P5 promoters; since the adaptor primers were not specific for a particular promoter; this
most likely reflects the predominance of P2- and P5-derived transcription in these cell types.
We did not observe any P1 transcripts in the sample of clones sequenced, which may reflect
the lower abundance of P1 transcripts. To determine the extent of the P5 exon, 45 cloned P5
50-RACE transcripts were sequenced (Fig 3). The results confirmed that P5 is a genuine alter-
native promoter region and that the P5 exon is approximately 70-bp in size. The TSS for P5
transcripts in activated CD4+ and activated CD19+ cells differed by only a few base-pairs, but
were distinct for each cell type (Fig 3). Potential ATG start codons are present in this 50-UTR
sequence, but they are not in frame with the coding sequence for PLAGL1.
A novel tissue-specific PLAGL1 promoter highly expressed in T cells
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Fig 2. Alternative splicing of PLAGL1 P5 transcripts isolated from A) activated CD4+ cell cDNA and B)
activated CD19+ cell cDNA. The locus is shown at the top with the location of the five PLAGL1 promoters
indicated, and exon ‘3a’ and ‘3b’ (not to scale).
https://doi.org/10.1371/journal.pone.0185678.g002
A novel tissue-specific PLAGL1 promoter highly expressed in T cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0185678 September 28, 2017 6 / 17
The P5 promoter region does not constitute a CpG island (CGI)
The P5 promoter lies ~9 kb downstream of the unmethylated P2 CGI and ~47 kb upstream of
the differentially methylated P1 promoter (Fig 2). No CGI is identified in this genomic region
by the UCSC Genome Browser. Using default parameters, MethPrimer (http://www.urogene.
org/methprimer/index1.html) does not identify any CGIs either (defined as regions >100-bp,
with a GC content >50% and an observed/expected CpG-rate of>0.6) within the 4-kb region
Fig 3. Transcriptional start sites identified for the PLAGL1 P5 promoter in activated CD4+ and activated CD19+ cells. The
complete P5 exon, as defined by 50-RLM-RACE in these cell types, is 70-bp in length (chr6:144,055,217–144,055,286; genome assembly
GRCh38/hg38). Arrows indicate the different transcriptional start sites identified in cloned 5’-RACE transcripts. The corresponding number
in the Table indicates the number of clones corresponding to that TSS and their prevalence, expressed as a percentage of the number of
clones sequenced.
https://doi.org/10.1371/journal.pone.0185678.g003
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surrounding the P5 start site. Similarly, analysis using PROMO 3.0 (www.algen.lsi.upc.edu/
recerca/menu_recerca.html) did not identify any CpG islands. However, ENCODE project
data (visualized using the UCSC genome browser) show epigenetic features suggesting a pro-
moter in this region. A DNAse I hypersensitivity site cluster overlaps the P5 exon and is
reported in 17 cell lines, most of which are of haemopoietic origin. A histone H3K27Ac mark
is also present, as an indicator of active regulatory elements [12].
Although no CGI is present, we used bisulphite sequencing to assess the methylation status
of the CpG sites near the P5 promoter, including two within the P5 first exon itself. We used
normal peripheral blood leukocyte DNA from three individuals (H1, H2 and H7); the P1 and
P2 CpG islands of H1 and H2 have been analyzed previously, showing them to be differentially
methylated (P1) and unmethylated (P2) [7]. Placenta genomic DNA, isolated from a single
donor, was also tested as it is a tissue with high expression of PLAGL1 [7], but it does not
appear to utilize P5 for transcription (Fig 1A).
The low CpG density necessitated sequencing of two amplicons to assess the methylation
status of a P5 genomic region spanning ten CpG sites (Fig 4). Amplicons containing CpG sites
1–3 (region 1) and 5–9 (region 2) were studied (highlighted as grey sequence; Fig 4A). The
fourth CpG site was not tested. A minimum of 14 plasmid colonies were sequenced, generated
from the cloning of each amplicon. CpG sites 1–3, located within the P5 first exon, were
unmethylated in all three leukocyte samples tested (Fig 4B), consistent with their location close
to an active TSS. These CpGs were also predominantly unmethylated in placenta genomic
DNA, a tissue that does not express P5 transcripts (Fig 4B). In contrast, CpG sites 5–9, located
within the first intron, were predominantly methylated in sample H1, H7 and placenta (for
sample H2, data were not obtained). We noticed that a small number of CpG sites in region 2
were no longer CpG dinucleotides (grey boxes); most were observed as TA.
Although some unmethylated CpG sites were observed in region 2, there was no evidence
of differential methylation of alleles in leukocytes or placenta to suggest genomic imprinting,
regardless of whether it was a P5-expressing or P5 non-expressing tissue.
P5 transcripts escape genomic imprinting and are biallelically expressed
The lack of differential methylation suggested that P5 transcripts may be derived from both
alleles. The allelic origin of P5 transcripts was determined using a single nucleotide polymor-
phism (SNP; rs2092894) located within an extended, alternatively-spliced version of exon 3 in
the 50-UTR of PLAGL1, as described previously [7]. The extended exon (which we have termed
‘exon 3b’) includes the 72-bp sequence ‘exon 3a’ but it is extended at the 3’ end where the SNP
is located (Fig 2). Therefore, the SNP is included within a subset of PLAGL1 transcripts. We
suspect that ‘exon 3b’ is a relatively large exon, as we have been unable to define the 3’ end by
RT-PCR using standard conditions.
In a heterozygous individual, rs2092894 is informative for all promoters due to its close
proximity to the alternative first exons within PLAGL1 transcripts. Using peripheral blood leu-
kocyte cDNA from such a heterozygous individual (H3), RT-PCR amplification of the 50-UTR
of transcripts from each PLAGL1 promoter was performed to assay for mono- or biallelic tran-
scription. In the same way, we have demonstrated that P1 promoter transcripts are monoallelic
and P2 transcripts are biallelic in peripheral blood leukocytes [7].
The resulting amplicons were cloned and individual clones were sequenced for each pro-
moter. As anticipated, P5 transcripts were derived from both alleles, confirming biallelic
expression from this promoter (Fig 5). Previously, P1 transcripts from the same individual
were found to be monoallelic, with transcription only from the G allele (assumed to be the
paternal allele), while P2 transcripts were biallelic [7].
A novel tissue-specific PLAGL1 promoter highly expressed in T cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0185678 September 28, 2017 8 / 17
Fig 4. Methylation analysis of CpG sites close to the P5 TSS in peripheral blood leukocytes and
placenta tissue. A) DNA sequence of the region close to the promoter P5 exon, written in the 50-30 orientation
with respect to PLAGL1 (chr6: 144054338–144055350; GRCh38/hg38). The 70-bp P5 exon is shown in bold.
The amplicons for methylation analysis are highlighted in grey, and the locations of PCR primers are
underlined. (Note: actual primer sequences are for bisulphite-converted DNA, see Materials and methods).
Amplicon 1: CpG sites 1–3, labelled from 50 end with respect to P5, are highlighted in white. CpG site 4 was
A novel tissue-specific PLAGL1 promoter highly expressed in T cells
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The P5 promoter is located within a MIR3 SINE retrotransposon
RepeatMasker analysis [13] (displayed in the UCSC genome browser) shows that the P5 pro-
moter exon lies within a SINE retrotransposon of the MIR3 class. MIR3 repeats (Mammalian-
wide Interspersed Repeat) are SINEs which exist only in mammals, and are the most ancient
not analyzed. Amplicon 2: CpG sites 5–9 highlighted in white (note that CpGs 5 and 6 are located within a
primer). A further CpG in the UCSC Genome browser reference sequence is a SNP (rs6901529). B)
Methylation analysis by bisulphite sequencing for the two separate amplicons for peripheral blood leukocyte
genomic DNA (individual H1 and H7, and amplicon 1 only for H2) and placenta genomic DNA. Squares
represent CpG sites: black indicates a methylated CpG site; white, an unmethylated CpG site. Grey shading
indicates a CpG site that was neither CG nor TG.
https://doi.org/10.1371/journal.pone.0185678.g004
Fig 5. Allelic expression of PLAGL1 transcripts derived from promoter P5, isolated from peripheral
blood leukocytes from a normal individual (sample H3), heterozygous for SNP rs2092894. A: SNP
alleles represented in cloned P5 transcripts indicate biallelic transcription as both alleles are represented.
Data for P1 and P2 for sample H3 have been published previously, showing monoallelic and biallelic
expression respectively [7]. B: Representative electropherograms of two cloned P5 transcripts indicating the
alternative alleles at the location of the SNP (arrows). The sequence shown is 5’-3’ with respect to the
PLAGL1 sequence. A representative sequence from this amplicon (clone 11; lower panel) has been
deposited in GenBank (MF361142).
https://doi.org/10.1371/journal.pone.0185678.g005
A novel tissue-specific PLAGL1 promoter highly expressed in T cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0185678 September 28, 2017 10 / 17
of transposable elements [14,15,16]. The SINE is 171-bp in length (chr6:144,055,219–
144,055,389; GRCh38/hg38), and it spans the whole P5 exon as defined by 5’ RLM-RACE,
except for 2-bp at the 30 end. Therefore, the P5 promoter appears to have evolved from the
insertion of this retrotransposon within the PLAGL1 locus.
BLAT searches revealed high nucleotide sequence conservation of the P5 exon in primates.
We detected an orthologous exon in the genomes of all primates available in the UCSC
genome browser, although the sequence was partially missing in baboon, either due to a
deletion or a gap in the published genomic sequence (Fig 6A). In chimp, this exon is also
identified in the UCSC genome browser as being within a MIR3 SINE (88-bp, located at
chr6:148,073,825–148,073,825; Chimp assembly Pan_tro 3.0/panTro5; May 2016). However,
we could not detect a similar promoter exon in any non-primate genomes, including mouse
and rat, suggesting that despite MIR3 being a mammalian-wide retrotransposon class, this
promoter has evolved relatively recently, since the divergence of primates, and may have been
subject to selective pressure for its retention [16]. Retrotransposons have been shown to con-
tribute to the formation of new promoters, such as a novel, tissue-specific KCNH5 promoter
that is transcriptionally active in placenta [17]. Of all retrotransposons, MIR sequences have
been found to be more frequently exonized within transcripts, possibly as a result of their
ancient origin [16].
Little published data is available on PLAGL1 expression in non-human primates, but it has
been found to be maternally imprinted in the cynomolgus macaque (Macaca fascicularis), with
evidence of biallelic expression in the liver [18]. For insight into the conservation of gene regu-
lation, we cloned and sequenced transcripts from the P1, P2 and P5 promoters in chimpanzee
(Pan troglodytes), using RNA extracted from the EB176(JC) lymphoblastoid cell line (Fig 6B;
see Materials and methods for accession numbers). Transcripts from all three promoters were
found to be expressed in chimp lymphoblastoid cells, and are highly similar to transcripts
from the human orthologue. They are alternatively spliced, and encode either the long or short
isoforms of the PLAGL1 protein, similar to human transcripts. The chimp P5 promoter region
from this lymphoblastoid cell line also showed a similar methylation pattern to the P5 region
in human leukocytes (S1 Fig), suggesting that P5 transcripts are biallelic in chimp. However,
the EB176 (JC) cell line is homozygous at rs2092894 and suitable alternative SNPs could not be
identified: therefore it was not possible to investigate genomic imprinting of transcripts from
the PLAGL1 promoters.
In conclusion, we have defined a novel, biallelically expressed PLAGL1 promoter (P5) that
is utilized predominantly in lymphocytes, particularly T cells. This provides further evidence
to support our previous observations [7,9] that PLAGL1 transcription escapes genomic
imprinting in human blood cells. The P1, P2 and P5 promoter exons are conserved between
humans and chimp and generate PLAGL1 transcripts. A similar methylation pattern is
observed at the P5 promoter region between humans and chimp, although we could not con-
firm conservation of monoallelic/biallelic expression due to a lack of informative SNPs.
As the P5 promoter exon appears to be present only in primates, it is likely that transcrip-
tional control by PLAGL/Plagl1 promoters in lymphocytes has diverged between humans and
mice. Therefore it is important that the biallelic origin of transcripts in human blood cells
(from the P2 and P5 promoters, rather than the imprinted P1, P3 and P4) is considered when
mice are used as a model system for imprinting studies of this gene.
It has been proposed that imprinting at the PLAGL1 locus is controlled by a 70-kb chroma-
tin loop around the gene, regulated by CTCF-cohesin binding [6]. Our observations are
consistent with this model, since the biallelic P2 and P5 promoters lie outside this domain.
Despite this, it is possible that there is regulatory crosstalk between the P5 promoter and
other PLAGL1 promoters, for example, through transcriptional interference [19]. SINE
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Fig 6. Fig 6A: Comparison of the 70-bp P5 exon sequence between human and eight primate species. Data is from the UCSC genome browser.
A dot indicates a conserved nucleotide compared to the human sequence, and ‘n’ indicates where sequence is not available. Fig 6B: Alternative
splicing of transcripts derived from the PLAGL1 P5 promoter, isolated from the Pan troglodytes lymphoblastoid cell line, EB176 (JC). The
PLAGL1 locus is shown at the top (not to scale). Transcripts from P1 and P2 were also isolated from EB176 (JC) and sequenced (accession numbers in
Materials and methods).
https://doi.org/10.1371/journal.pone.0185678.g006
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retrotransposons can epigenetically reprogram gene promoters [20], and MIR retrotransposon
sequences have been shown to function as insulators [21] or enhancers [16] within the human
genome.
PLAGL1 expression has been reported in CD4+ T cells from cord blood [22]. In mouse,
Plagl1 is active in T regulatory cells [23] and long term repopulating haematopoietic stem cells
(LT-HSCs) [24]. Its expression has been found to distinguish between expression profiles in
murine follicular helper cells (Tfh) and T helper 1 cells (Th1) cell populations [25]. As tran-
scription is driven by P2 and P5 promoters in human blood cells, a more complex view of
PLAGL1 regulation and function is essential when considering loss of its expression in cells of
haemopoietic origin and in haematological malignancies.
Materials and methods
RNA and DNA samples
A human tissue RNA panel (First Choice Human Total RNA Survey panel) and human
peripheral blood leukocyte RNA were purchased from Ambion (ThermoFisher Scientific).
Human blood cell RNA samples from CD4+, CD8+, CD14+ and CD19+ blood cell lineages
were purchased from Yorkshire Bioscience, York, UK (http://york-bio.com/). Natural killer
(NK) cell RNA (single donor) was kindly provided by Dr. Y. El-Sherbiny, School of Medicine,
University of Leeds. All commercially-sourced RNA samples were derived from pooled cells
from several donors. Genomic DNA samples were from peripheral blood leukocytes from
three separate donors and placenta DNA was from a single, female donor (D3035; Sigma).
For Yorkshire Bioscience blood cell RNA samples, full details of blood cell isolation and in
vitro activation prior to RNA extraction are available on the manufacturer’s website at http://
york-bio.com/blood_cells_rna.htm. In brief, activated CD4+ cells were isolated after CD8+,
CD19+ and partially CD14+-depleted mononuclear (MN) cells had been treated with 5mg/ml
concanavalin A (ConA) for 3–4 days. Activated CD8+ cells were positively selected by immu-
nomagnetic separation from CD14+ and CD4+-depleted MN cells following incubation with
5mg/ml phytohemagglutinin (PHA) for 3 days. Activated CD19+ cells were positively selected
from CD14+ and CD8+-depleted MN cells following incubation with 2mg/ml pokeweed mito-
gen (PWM) for 4 days (Yorkshire Bioscience).
The chimpanzee lymphoblastoid cell line EB176(JC) was obtained from ECACC, and main-
tained in RPMI with glutamine and 15% foetal calf serum at 37˚C, 5%CO2. RNA and DNA
were prepared using Trizol (ThermoFisher) or the QIAamp DNA Mini kit (Qiagen),
respectively.
Reverse transcription PCR (RT-PCR)
First-strand cDNA synthesis was carried out using the ThermoScript™ RT-PCR system (Ther-
moFisher Scientific), with random hexamers according to the manufacturer’s instructions. For
Fig 1A and 1B, three individual PCR reactions were performed for each tissue, using forward
primers that specifically amplify transcripts from either the P1, P2 or P5 promoter, combined
with a common reverse primer (located in the coding region in the final exon) in separate reac-
tions. The same quantity of cDNA template was used in each PCR reaction. Forward primers:
P1, dCTGAGCTCCGGGGGTCGT;P2, dGCTCCGGACTCCAGAACTT;P5, dCGGTAAGCTTTCTT
CTCTGTCGAAC. Reverse primer: dACACTGGTGAGATTTCTGGGGAGAAT. PCR conditions
were 95˚C, 5 min; followed by 35 cycles of 95˚C for 30 s; 60˚C for 30 s; 72˚C for 30 s; with a
final extension step of 72˚C for 3 min.
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Cloning and sequencing of transcripts
For sequencing, transcripts were ligated into pGEM1-T Easy vector (Promega), transformed
into DH5α cells (Invitrogen) and plated on LB agar plates containing ampicillin, X-gal and
IPTG (Sigma). Plasmid DNA was prepared from individual colonies using a GenElute Plasmid
Miniprep kit (Sigma) and was sequenced using a BigDye1 v.3.1 Cycle Sequencing kit (Ther-
moFisher). Sequencing was carried out in both directions, and reactions were analysed on an
Applied Biosystems ABI3130xl sequencer using Sequencing Analysis v5.2 software. Accession
numbers: Fig 2A) activated CD4+ cell transcripts: MF084771; MF084772; MF084773;
MF084774; MF084775; MF084776; MF084777; MF084778; MF084779; MF084780; Fig 2B)
activated CD19+ cell transcripts: MF084781; MF084782; MF084783; MF084784; MF084785;
MF084786; MF084787; Fig 6B) Chimp lymphoblastoid cell EB176(JC) transcripts generated
from Promoter 5: MF361132; MF361133; MF361134; MF361135; MF361136 Additional
chimp transcripts for Promoter 1; MF361137; MF361138; and Promoter 2: MF361139;
MF361140; MF361141.
Quantitative (Real-Time) PCR (qPCR)
QPCR was carried out using Taqman PCR reagents, according to the manufacturer’s instruc-
tions (Life Technologies, ThermoFisher Scientific). cDNA was generated from blood cell and
tissue RNA, as described above. Reactions were performed on an ABI 7900HT Real-Time PCR
system and analyzed using SDS v.2.3 software. Custom-made Taqman assays were used for the
PLAGL1 P2 or P5 promoters. The P5 assay was designed to specifically amplify transcripts
containing the P5 first exon, the second and third exons of the 5’UTR. The probe was designed
to cross the P5 exon-exon 2 boundary in transcripts. Experimental cDNA samples were run
with either the P2 or P5 assay, in tandem with an assay to the endogenous control gene RPLP0
(4333761F; Life Technologies), in separate reactions on the same plate. Expression of RPLP0
was used to normalize PLAGL1 expression for each sample.
The absolute quantification method was used for analysis: dilution series for standard
curves were generated using CD4+ RNA (Yorkshire Bioscience) for the P5 analysis, and
peripheral blood leukocyte RNA (Ambion) for the P2 analysis. Samples were run in triplicate
with no template controls (NTC) included. NTC wells were negative in all cases. Details of the
P2 Taqman assay (assay P2b) have been published previously [7]. Sequences for the P5 assay
were as follows: Forward primer dGCTTTCTTCTCTGTCGAACACACT; reverse primer
dGCAATCAAAAGCCAATCACGATGTT; probe 6FAM-dCAGGAACAATCCAGAAACA.
50 RLM-RACE
For 50-RACE experiments, the FirstChoice RLM-RACE kit was used (Ambion), according to
the manufacturer’s instructions, with activated CD4+ and activated CD19+ RNA (Yorkshire
Bioscience). Nested reverse primers to exon 3a were used in two rounds of PCR: 1st round:
50 RACE Outer Primer (Ambion) and reverse primer dATGTGACACGAGGCAGCAG;2nd round
50 RACE Inner Primer (Ambion) and reverse primer dGCCACATTAGACGTGACAGC.Ambion
primers were designed to the ‘50 RACEAdapter’ sequence at the 50 end, and PLAGL1 reverse
primers were designed to exon ‘3a’.
Methylation analysis by bisulphite sequencing
Bisulphite conversion of peripheral blood leukocyte genomic DNA was carried out using the
EpiTect Bisulfite kit (Qiagen). Two adjacent genomic regions were PCR-amplified: amplicon 1
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contained CpG sites 1–3 and amplicon 2 contained CpG sites 5–9. PCR primers were designed
to amplify methylated and unmethylated sequences non-selectively. Primers were:
P5 Amplicon 1 Forward, dGTGGGTTGTGGTTTTGGTGT;
P5 Amplicon 1 Reverse, dTTCCATCCAAATATTATTAAAACTCAA;
P5 Amplicon 2 Forward, dTGTTTYGGGATATATGGGTATAAYGT;
P5 Amplicon 2 Reverse, dAAAACCAACCCAAATAACCATT.
The region around CpG site 4 was not analysed as suitable primers could not be designed.
Bisulphite PCR was performed as follows: 94˚C, 3 min; 35 cycles of 94˚C for 30 s, 58˚C for 30
s, 72˚C for 30 s; with a final extension step of 72˚C for 3 min. PCR products were cloned into
DH10B cells (Invitrogen), sequenced and analysed as described previously [9]. Sequencing
was carried out in both directions, and analysis was carried out using CpGviewer (http://dna.
leeds.ac.uk/cpgviewer) [26]. For methylation of the chimp P5 promoter, the same procedure
was carried out using DNA extracted from the EB176 (JC) cell line and the same primers as
above.
Analysis of allelic expression of P5 transcripts
For biallelic or monoallelic expression analysis of promoter P5, SNP rs2092894 was used
(dbSNP, NCBI), as described previously for assessing P1 and P2 [7]. Peripheral blood leuko-
cyte RNA was from a single, heterozygous donor (H3), and was reverse-transcribed as
described above. For RT-PCR of PLAGL1 transcripts, a forward primer specific for the P5
first exon was used, combined with a reverse primer to exon ‘3b’ (Fig 2): P5 forward,
dCGGTAAGCTTTCTTCTCTGTCGAAC; reverse primer: dTGGTGGACCCTACCTCAGTT.PCR
products were cloned and individual clones were sequenced, as described above, to determine
the number of transcripts from each allele. Accession number for a representative transcript
(see Fig 5B; clone 11): MF361142.
Supporting information
S1 Fig. Methylation analysis of the chimpanzee P5 promoter region using DNA from
chimp lymphoblastoid cells. The same CpG sites were analysed as for the methylation analy-
sis of the human P5 promoter region (Fig 4) using the same primers (see Materials and meth-
ods). A similar methylation pattern was observed compared to human leukocytes (Fig 4B).
(TIF)
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